Epigenetic Signatures

Genomic and Inherited Disorders

01-EPI-27

EQA for clinical DNA methylation-based episignature analysis. Please contact office@emqn.org if you are interested in participating in this EQA.

Overview

This EQA will provide independent assessment, external benchmarking and educational feedback for laboratories performing episignature testing and will evaluate both the technical generation of methylation data and the clinical interpretation of episignature results.

At a glance

Product Code:

01-EPI-27

Target/Genes:

Assessment of episignature methylation analysis

Technology:

Array based, Methylation

Sample Type:

DNA (in TE Buffer)

Submit Results In:

Polish

Accredited:

No

Key Dates

Register by

09/11/2026

Samples ship

To be finalised

Survey Period

To be finalised (for exact dates, please see scheme instructions)

Final Results

To be finalised (for exact dates, please see scheme instructions)

Sample Details

More detail to be provided

EQA Results

Participants will receive an individual report including educational advice and a scheme report which includes additional information from the cohort of participants including geographical spread, methodologies employed, common errors, learning points and scheme statistics allowing participants to benchmark their results.

Each laboratory will also receive a single certificate listing all EQAs participated in with performance result for each year.

Participation Information

Participants are expected to test samples according to their routine strategy, to return a clinical report and to complete the data collection form.

Please contact office@emqn.org if you are interested in participating in this EQA.

Send your enquiry by submitting the form

Closing Soon

Closes today

From £650.00

Buying is completed on the EMQN portal and needs a free EMQN account, which takes a few minutes to set up.

Add to enquiry list
  • Submit results in 1 language

Questions about this scheme?
Contact our team

Register Interest

Express your interest in ''.

Watch on YouTube (opens in a new tab)